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Around the world, large-scale biomonitoring programs have provided 
extensive information about human exposure to a large number 
of environmental chemicals (Barr et al. 2010; Bilau et al. 2008; 
Churchill et al. 2001; Woodruff et al. 2011). As these programs 
extend to look at vulnerable populations, including pregnant women, 
fetuses, and the elderly, our knowledge of the widespread distribu-
tion of many of these chemicals—including hundreds that have been 
classified as endocrine disruptors—continues to climb. However, 
the mere presence of a chemical in humans is not necessarily cause 
for concern. What is concerning is the increasing number of epide-
miological studies showing associations between the concentration 
of these chemicals in the general population and adverse health 
end points (Braun and Hauser 2011; Crain et al. 2008). Although 
high exposures following accidental or occupational exposures to 
endocrine disruptors, industrial chemicals, pesticides, and pharma-
ceuticals have shown striking effects, epidemiological studies suggest 
that low doses may also be unsafe, even for populations that are not 
typically considered “vulnerable.” 
Making connections between the exposome and risk assessment is 
a difficult but important venture (Paustenbach and Galbraith 2006; 
Rappaport and Smith 2010). Risk assessments typically examine the 
effects of high doses of adminis  tered chemicals to determine the lowest 
observed adverse effect levels (LOAELs) and no observed adverse effect 
levels (NOAELs); reference doses, which are assumed safe for human 
exposure, are then calculated from these doses using a number of 
safety factors. Thus, human exposures to thousands of environ  mental 
chemicals fall in the range of non  negligible doses that are thought 
to be safe from a risk assessment perspective. Yet the ever-increasing 
data from human biomonitoring and epidemiological studies suggests 
otherwise: Low internal doses of endocrine disruptors found in typical 
human populations have been linked to obesity (Carwile and Michels 
2011), infertility (Meeker and Stapleton 2010), neuro  behavioral 
disorders (Swan et al. 2010), and immune dysfunction (Miyashita 
et al. 2011), among others. 
For several decades, environmental health scientists have been 
dedicated to addressing the “low-dose hypothesis,” which postulates 
that low doses of chemicals can have effects that would not necessarily 
be predicted from their effects at high doses. More than 10 years ago, 
a National Toxicology Program expert panel concluded that there 
was evidence for low-dose effects for a select number of well-studied 
endocrine disruptors (Melnick et al. 2002). Now, a diverse group of 
scientists has reexamined this large body of literature, finding examples 
of low-dose effects for dozens of chemicals across a range of chemical 
classes, including industrial chemicals, plastic components and plasti-
cizers, pesticides, phyto  estrogens, preservatives, surfactants and deter-
gents, flame retardants, and sunblock, among others (Vandenberg 
et al. 2012). Vandenberg et al. selected several examples of controver-
sial low-dose test cases and applied an analytical weight-of-evidence 
approach to determine whether there was sufficient evidence to con-
clude that particular environmental chemicals had effects on specific 
biological end points. Their analysis addresses how experimental 
design, choice of animal strain/species, study size, and inclusion of 
appropriate controls affect the outcome and interpretation of studies 
on bisphenol A (BPA), atrazine, dioxin, and perchlorate. Their study 
provides important insight into the effects of 
environ  mental chemicals on health-related 
end points and addresses the mecha  nistic ques-
tions of how chemicals with hormonal activity 
can have effects at external doses that are often considered safe by the 
regulatory community.
Vandenberg et al. (2012) have also collected several hundred 
examples of non  monotonic dose–response curves (representing 
many classes of environmental chemicals) that have been observed in 
cultured cells, animals, and even human populations (Vandenberg 
et al. 2012). Most importantly, they reviewed the voluminous 
endocrine literature on how and why non  linear responses manifest at 
different levels of biological complexity, including the combination of 
competing monotonic responses (such as enhanced cell proliferation 
and cytotoxicity), the expression of cell- and tissue-specific cofactors 
and receptors, and receptor down-regulation, desensitization, and 
competition. Thus, the question is no longer whether non  monotonic 
dose responses are “real” and occur frequently enough to be a 
concern; clearly these are common phenomena with well-understood 
mechanisms. Instead, the question is which dose–response shapes 
should be expected for specific environmental chemicals and under 
what specific circumstances. 
Moving forward, studies of suspected endocrine disruptors need to 
include doses that result in relevant internal human levels and examine 
a wide range of biological end points. Dose–response studies should 
include a range of doses to distinguish between linear monotonic 
and non  monotonic responses. Non  linear relationships should not be 
dismissed. Collaborations between research scientists in academia, 
government, and industry should be encouraged to allow for develop-
ment of more sophisticated study designs to facilitate regulatory 
decisions. It is time to start the conversation between environmental 
health scientists, toxicologists, and risk assessors to determine how our 
understanding of low-dose effects and non  monotonic dose responses 
influence the way risk assessments are performed for chemicals with 
endocrine-disrupting activities. Together, we can take appropriate 
actions to protect human and wildlife populations from these harmful 
chemicals and facilitate better regulatory decision making.
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